BRAF and melanoma: Notwithstanding the current decline in melanoma-associated mortality attributed to modalities encompassing immune checkpoint therapy, targeted therapeutic approaches, radiotherapy, and chemotherapy6, notably in the context of the B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 (Val600) mutation, the application of select BRAF inhibitors in conjunction with schizogen-activated protein kinase inhibitors has evinced a substantial enhancement in treatment response and overall survival rates7.